<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495391</url>
  </required_header>
  <id_info>
    <org_study_id>RM01-2025</org_study_id>
    <nct_id>NCT00495391</nct_id>
  </id_info>
  <brief_title>Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C</brief_title>
  <acronym>STEALTHC-2</acronym>
  <official_title>Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Patients With Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romark Laboratories L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Romark Laboratories L.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if nitazoxanide in combination with peginterferon
      alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in patients that
      have previously failed to respond to treatment with peginterferon and ribavirin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)</measure>
    <time_frame>24 weeks after end of treatment</time_frame>
    <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection 24 weeks after the end of treatment. All others were considered non-responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End of Treatment Response (HCV RNA Below Lower Limit of Detection)</measure>
    <time_frame>At end of treatment</time_frame>
    <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection at the end of treatment. All others were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Virologic Response (HCV RNA Below Lower Limit of Detection)</measure>
    <time_frame>After 12 weeks combination treatment</time_frame>
    <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection after 12 weeks of combination therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)</measure>
    <time_frame>After 4 weeks combination treatment</time_frame>
    <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection after 4 weeks of combination therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALT</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALT</measure>
    <time_frame>From baseline to week 16</time_frame>
    <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALT</measure>
    <time_frame>From baseline to end of treatment</time_frame>
    <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALT</measure>
    <time_frame>From baseline to end of follow up</time_frame>
    <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Alinia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One oral placebo tablet twice daily for 52 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>PEGASYS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>COPEGUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C genotype 1.

          -  Failed to respond to ≥12 weeks of peginterferon and ribavirin (&lt;2 log10 drop in
             Hepatitis C Virus Ribonucleic Acid (HCV RNA) at week 12 or detectable Hepatitis C
             Virus Ribonucleic Acid (HCV RNA) at week 24).

        Exclusion Criteria:

          -  Females of child-bearing age who are either pregnant, breast-feeding or not using
             birth control and are sexually active.

          -  Males whose female partners are either pregnant or of child-bearing potential or not
             using birth control and are sexually active.

          -  Other causes of liver disease including autoimmune hepatitis.

          -  Transplant recipients receiving immune suppression therapy.

          -  Screening tests positive for Anti-Hepatitis A Virus Immunoglobulin M Antibody
             (anti-HAV IgM Ab), Hepatitis B's antigen (HBsAg), Anti-Hepatitis B core antigen
             Immunoglobulin M Antibody (anti-HBc IgM Ab) or Anti-Human Immunodeficiency Virus
             Antibody (anti-HIV Ab).

          -  Decompensated cirrhosis, history of variceal bleeding, ascites, hepatic
             encephalopathy, Child-Turcotte-Pugh (CTP) score &gt;6 or Model for End-stage Liver
             Disease (MELD) score &gt;8.

          -  Alcohol consumption of &gt;40 grams per day or an alcohol use pattern that will interfere
             with the study.

          -  Absolute neutrophil count &lt;1500 cells/mm3; platelet count &lt;135,000 cells/mm3;
             hemoglobin &lt;12 g/dL for women and &lt;13 g/dL for men; or serum creatinine concentration
             ≥1.5 times Upper Limit of Normal (ULN).

          -  Hypothyroidism or hyperthyroidism not effectively treated with medication.

          -  Hemoglobin A1C (HgbA1c) &gt;7.5 or history of diabetes mellitus.

          -  Body Mass Index (BMI) &gt;28.

          -  History or other clinical evidence of significant or unstable cardiac disease.

          -  History or other clinical evidence of chronic pulmonary disease associated with
             functional impairment.

          -  Serious or severe bacterial infection(s).

          -  Ulcerative or hemorrhagic/ischemic colitis.

          -  Pancreatitis.

          -  History of severe or uncontrolled psychiatric disease, including severe depression,
             history of suicidal ideation, suicidal attempts or psychosis requiring medication
             and/or hospitalization.

          -  History of uncontrolled severe seizure disorder.

          -  Requires concomitant theophylline or methadone.

          -  History of immunologically mediated disease requiring more than intermittent
             anti-inflammatory medications for management or that requires frequent or prolonged
             use of corticosteroids.

          -  History or other evidence of severe retinopathy or clinically relevant
             ophthalmological disorder due to diabetes mellitus or hypertension.

          -  Hemoglobinopathies.

          -  History of hypersensitivity or intolerance to nitazoxanide or any of the excipients
             comprising the nitazoxanide tablets, peginterferon alfa-2a injectable solution or
             ribavirin tablets.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida Hepatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Harrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur Berman, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Center for Gastroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Pruitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nashville Medical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Aijaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramsey Cheung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Palo Alto Healthcare System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ira Jacobson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell Shiffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGuire VA Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University Digestive Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norman Gitlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta Gastroenterology Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Healthcare System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University Digestive Diseases</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Hepatology</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Center for Gastroenterology</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Medical Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <results_first_submitted>November 18, 2013</results_first_submitted>
  <results_first_submitted_qc>November 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2014</results_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study recruited patients from 10 study sites in the United States, including a Veterans Administrations hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>NTZ+PR</title>
          <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo+PR</title>
          <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>From Baseline to Week 8</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>From Baseline to Week 16</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>From Baseline to End of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>From Baseline to End of Follow up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NTZ+PR</title>
          <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo+PR</title>
          <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="8"/>
                    <measurement group_id="B2" value="53" spread="6"/>
                    <measurement group_id="B3" value="53.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)</title>
        <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection 24 weeks after the end of treatment. All others were considered non-responders.</description>
        <time_frame>24 weeks after end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NTZ+PR</title>
            <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+PR</title>
            <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)</title>
          <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection 24 weeks after the end of treatment. All others were considered non-responders.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End of Treatment Response (HCV RNA Below Lower Limit of Detection)</title>
        <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection at the end of treatment. All others were considered non-responders.</description>
        <time_frame>At end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NTZ+PR</title>
            <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+PR</title>
            <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>End of Treatment Response (HCV RNA Below Lower Limit of Detection)</title>
          <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection at the end of treatment. All others were considered non-responders.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Virologic Response (HCV RNA Below Lower Limit of Detection)</title>
        <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection after 12 weeks of combination therapy.</description>
        <time_frame>After 12 weeks combination treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NTZ+PR</title>
            <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+PR</title>
            <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Early Virologic Response (HCV RNA Below Lower Limit of Detection)</title>
          <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection after 12 weeks of combination therapy.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)</title>
        <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection after 4 weeks of combination therapy.</description>
        <time_frame>After 4 weeks combination treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NTZ+PR</title>
            <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+PR</title>
            <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)</title>
          <description>Hepatitis C Virus Ribonucleic Acid (HCV RNA) below lower limit of detection after 4 weeks of combination therapy.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in ALT</title>
        <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
        <time_frame>From baseline to week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NTZ+PR</title>
            <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+PR</title>
            <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in ALT</title>
          <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remains Elevated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated to Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remains Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal to Elevated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in ALT</title>
        <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
        <time_frame>From baseline to week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NTZ+PR</title>
            <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+PR</title>
            <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in ALT</title>
          <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remains Elevated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated to Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remains Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal to Elevated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in ALT</title>
        <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
        <time_frame>From baseline to end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NTZ+PR</title>
            <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+PR</title>
            <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in ALT</title>
          <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remains Elevated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated to Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remains Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal to Elevated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in ALT</title>
        <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
        <time_frame>From baseline to end of follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NTZ+PR</title>
            <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+PR</title>
            <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in ALT</title>
          <description>This analysis was conducted using a comparison of changes in Alanine aminotransferase (ALT) from baseline through week 8, week 16, end of treatment and end of follow up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Remains Elevated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated to Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remains Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal to Elevated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NTZ+PR</title>
          <description>Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Nitazoxanide : One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo+PR</title>
          <description>Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if &lt;75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
Ribavirin : 1000 mg (if &lt;75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
Peginterferon alfa-2a : Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
Placebo : One oral placebo tablet twice daily for 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Kidney Calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Edema Larynx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="42"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain Abdo</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Constip</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Liver Func Abnorm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="42"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain Back</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Flu Synd</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cramps Leg</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cough Inc</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Skin Dry</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Presentation and/or publication is encouraged provided the Sponsor is notified in advance and given the opportunity to review the manuscript or abstract 30 days prior to its submission for presentation at a scientific meeting or for publication in a scientific journal. The investigators will have complete autonomy regarding the content and wording including the decision of whether or not to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc Ayers</name_or_title>
      <organization>Romark Laboratories, L.C.</organization>
      <phone>813-282-8544</phone>
      <email>Marc.Ayers@romark.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

